Checkmate 214 post-hoc analyses of nivolumab plus ipilimumab or sunitinib in intermediate/poor-risk patients with previously untreated advanced renal cell carcinoma with sarcomatoid features - McDermott, D F; Choueiri, T K; Motzer, R J (J Clin Oncol, 2019)
et al.